A large study adds to our knowledge on the topic.
Immunizations are beneficial for people with multiple sclerosis (MS), particularly those taking immunocompromising medications (NEJM JW Neurol Aug 29 2019 and Neurology 2019; 93:584). Investigators used the French System of National Health Databases to identify patients with MS who received vaccination to determine risk for disease flare-up requiring hospitalization. They identified a cohort of 106,523 patients with MS who were followed for a mean of 9 years.
One third of the cohort were hospitalized for MS relapses. The odds for vaccine exposure in the 60 days before the hospitalization for relapse was 1.0 (95% confidence interval, 0.92–1.09) for all vaccines. Similar results were observed for DTP/Polio/Haemophilus influenzae, influenza, an…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)